Difference between revisions of "Ber-EP4"
Jump to navigation
Jump to search
(create) |
|||
| Line 6: | Line 6: | ||
==Negative== | ==Negative== | ||
*[[ | *[[Squamous cell carcinoma of the skin]]. | ||
*[[Malignant mesothelioma]] (18 of 70 cases<ref name=pmid9426522/>). | *[[Malignant mesothelioma]] (18 of 70 cases<ref name=pmid9426522/>). | ||
*[[Microcystic adnexal carcinoma]].<ref name=pmid23398472 >{{Cite journal | last1 = Sellheyer | first1 = K. | last2 = Nelson | first2 = P. | last3 = Kutzner | first3 = H. | last4 = Patel | first4 = RM. | title = The immunohistochemical differential diagnosis of microcystic adnexal carcinoma, desmoplastic trichoepithelioma and morpheaform basal cell carcinoma using BerEP4 and stem cell markers. | journal = J Cutan Pathol | volume = 40 | issue = 4 | pages = 363-70 | month = Apr | year = 2013 | doi = 10.1111/cup.12085 | PMID = 23398472 }}</ref> | |||
==See also== | ==See also== | ||
Revision as of 16:23, 15 May 2016
Ber-EP4 is a commonly available immunostain.
Positive
- Basal cell carcinoma.
- Lung adenocarcinoma (55 of 59 cases[1]).
Negative
- Squamous cell carcinoma of the skin.
- Malignant mesothelioma (18 of 70 cases[1]).
- Microcystic adnexal carcinoma.[2]
See also
References
- ↑ 1.0 1.1 Ordóñez, NG. (Jan 1998). "Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.". Am J Clin Pathol 109 (1): 85-9. PMID 9426522.
- ↑ Sellheyer, K.; Nelson, P.; Kutzner, H.; Patel, RM. (Apr 2013). "The immunohistochemical differential diagnosis of microcystic adnexal carcinoma, desmoplastic trichoepithelioma and morpheaform basal cell carcinoma using BerEP4 and stem cell markers.". J Cutan Pathol 40 (4): 363-70. doi:10.1111/cup.12085. PMID 23398472.